Marie Wikström Lindholm

Marie Wikström Lindholm, Ph.D. joined Silence Therapeutics in December 2017 as Head of Molecular Design where she leads a skilled team focusing on fine-tuning the design of GalNAc-conjugated siRNA and exploring siRNA delivery outside the hepatocyte.

Dr. Lindholm has more than 13 years of experience with oligonucleotide therapeutics, starting with Santaris Pharma A/S, Denmark, working on locked nucleic acid (LNA) oligonucleotide drug discovery from molecule design through in vitro screening, in vivo activity, and metabolism studies, and finally a role as lipid metabolism expert. When Santaris was acquired by Roche in 2014, Dr. Lindholm was appointed Expert Scientist in Discovery Technology and Head of Targeted Delivery of oligonucleotide conjugates. She was also a scientific coordinator for the LNA work in two large EU-funded FP7 programs (AtheroBCell and Athero Flux).

Before the transition to industry, Dr. Lindholm had an international academic career in experimental cardiovascular research starting with a Ph.D. from Uppsala University. She has authored over 60 patents and peer-reviewed scientific publications, many in the fields of oligonucleotide drug design, safety, and function.